Best treatments for gastroparesis
1 product may treat gastroparesis, spanning FDA drug classes such as dopamine-2 receptor antagonist. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.
Understanding gastroparesis
Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from your stomach to your small intestine. The muscles in the stomach wall work poorly or not at all, and the stomach takes too long to empty its contents. Symptoms may include feeling full soon after starting a meal, feeling full long after eating a meal, nausea, vomiting, too much bloating, pain in the upper abdomen, heartburn, and poor appetite. Complications may include dehydration from repeated vomiting, malnutrition from poor absorption of nutrients, blood glucose levels that are harder to control, losing weight without trying, and lower quality of life. In most cases doctors cannot find the underlying cause even with medical tests, which is called idiopathic gastroparesis. Diabetes is the most common known underlying cause. Other known causes include injury to the vagus nerve from surgery on the esophagus, stomach, or small intestine, hypothyroidism, autoimmune diseases such as scleroderma, nervous system disorders such as Parkinson's disease and multiple sclerosis, and viral infections of the stomach. It is not common: out of 100,000 people, about 10 men and about 40 women have gastroparesis. Doctors diagnose it from medical history, a physical exam, symptoms, and medical tests. Imaging can show a stomach blockage or intestinal obstruction, and an upper GI endoscopy looks for problems in the upper digestive tract. Tests that measure how fast the stomach empties include a gastric emptying scan, a gastric emptying breath test, and a wireless motility capsule. This page is general information, not medical advice.
First-line treatment
The American Gastroenterological Association's clinical guideline on the management of gastroparesis, published September 19, 2025, offers 12 conditional recommendations and emphasizes shared decision-making between clinicians and patients. On testing, AGA suggests against a two-hour or shorter gastric emptying study compared with a four-hour study; the earlier American College of Gastroenterology 2022 guideline recommends scintigraphic gastric emptying of a solid meal lasting at least three hours. On drug therapy, AGA suggests using metoclopramide and suggests using erythromycin, and suggests against domperidone, prucalopride, aprepitant, nortriptyline, and buspirone as first-line treatments. The ACG's Evidence-Based GI summary of that guideline describes initial treatment as focusing on a small-particle diet, and notes that metoclopramide is the only FDA-approved medication for gastroparesis. For symptoms refractory to medical therapy, AGA suggests against routine botulinum toxin injection, routine gastric peroral endoscopic pyloromyotomy, and routine gastric electrical stimulation. Because these are conditional recommendations, the choice of treatment is made by a clinician with each patient; none of these options is described as a cure.
Full ranking · 1 treatments
Frequently asked
- What treats gastroparesis?
- Our catalog lists 1 product that may treat gastroparesis, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists.
- What is the best-rated treatment for gastroparesis?
- Ratings appear as FDA recall-safety data accumulates for the products that may treat gastroparesis.
- How are these treatments ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
- What types of drugs treat gastroparesis?
- Treatments for gastroparesis span FDA drug classes including dopamine-2 receptor antagonist. Compare every option side by side, ranked by independent rating, above.
Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.
Sources
The clinical overview above is written from these authoritative public-health and medical-society sources, independently reviewed against each.
- Definition & Facts for Gastroparesis — NIDDK (NIH) ↗
- Symptoms & Causes of Gastroparesis — NIDDK (NIH) ↗
- Diagnosis of Gastroparesis — NIDDK (NIH) ↗
- Clinical guidance on the management of gastroparesis (2025) — American Gastroenterological Association ↗
- ICYMI: 2022 ACG Clinical Guideline — Gastroparesis — American College of Gastroenterology, Evidence-Based GI ↗